Vinorelbine and low dose cyclophosphamide in pediatric sarcoma. A pilot study for the future European rhabdomyosarcoma protocol

Casanova, M.; Ferrari, Alessandra; Bisogno, Gianni; Merks, Johannes H. M.; Salvo, Gian Luca De; Tettoni, K.; Provenzi, Massimo; Bellani, F. Fossati; Carli, Modesto

doi:10.1200/jco.2004.22.90140.8540

Cited by 10 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At least three small studies of metronomic chemotherapy have included patients with Ewing sarcoma, with some indication of disease stabilization with this approach (Table 2). 46–48 The COG has completed a pilot feasibility study of the addition of celecoxib and thrice-weekly vinblastine along with a conventional chemotherapy backbone in 36 patients with newly diagnosed metastatic Ewing sarcoma. The results of this study are anticipated shortly.…”

Section: Anti-angiogenic and Anti-vascular Therapies For Patients Witmentioning

confidence: 99%

Angiogenesis and vascular targeting in Ewing sarcoma

DuBois

Marina

Bender

2009

Cancer

View full text Add to dashboard Cite

Ewing sarcoma is the second most common type of bone cancer in children and young adults. In recent years, the mechanisms by which these tumors develop and maintain their vascular supply have been elucidated. Additional work has demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of Ewing sarcoma mouse xenografts. Early clinical data suggest that these results also may extend to patients with Ewing sarcoma who are treated with antiangiogenic or antivascular therapies. For the current review, the authors summarized the available data supporting this approach. Cancer 2010. © 2009 American Cancer Society.

show abstract

Section: Anti-angiogenic and Anti-vascular Therapies For Patients Witmentioning

confidence: 99%

Angiogenesis and vascular targeting in Ewing sarcoma

DuBois

Marina

Bender

2009

Cancer

View full text Add to dashboard Cite

show abstract

“…The duration of response is also low, from 6 to 14 months. More recently, topotecan or vinorelbine have been tested without success 10, 11, 12. To date, no standard second‐line chemotherapy has been developed, although ET743 has been reported to yield high progression free rates in several different phase II trials 13…”

mentioning

confidence: 99%

Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis

Bay

Ray‐Coquard

Fayette

et al. 2006

Intl Journal of Cancer

166

104

View full text Add to dashboard Cite

Advanced soft‐tissue sarcomas are usually resistant to cytotoxic agents such as doxorubicin and ifosfamide. Antitumor activity has been observed for gemcitabine and docetaxel combination. We conducted a retrospective study on 133 patients (58 males/75 females) with unresectable or metastatic soft‐tissue sarcoma. The median age at diagnosis was 51.7 (18–82), with 76 patients with leiomoyosarcoma and 57 patients with other histological subtypes. The initial localizations were limb (44), uterine (32), retroperitoneal (23) and organs or bone (34). Patients received 900 mg/m2 of gemcitabine (days 1 and 8) over 90 min plus 100 mg/m2 of docetaxel (day 8), intravenously every 21 days. Gemcitabine/docetaxel combination was well tolerated with an overall response of 18.4% and with no clear statistical difference between leiomyosarcomas and other histological subtypes (24.2% versus 10.4% (p = 0.06)). No difference was found between uterine soft‐tissue sarcomas versus others. The median overall survival was 12.1 months (1–28). Better overall survival was correlated with leiomyosarcoma (p = 0.01) and with the quality of the response, even for patients with stable disease (p < 10−4). No statistical difference was found for the initial localization. Response to treatment and overall survival were better for patients in World Health Organization (WHO) performance status classification (PS) 0 at baseline versus patients in WHO PS‐1, 2 or 3 (p = 0.023 and p < 10−4, respectively). Gemcitabine/docetaxel combination was tolerable and demonstrated better response and survival for leiomyosarcoma, especially for patients in WHO PS‐0 at baseline. For the other histological subtypes, the response was not encouraging, but the survival for patients in response or stable suggests further investigation. © 2006 Wiley‐Liss, Inc.

show abstract

“…Oral cyclophosphamide proved to be active in combination with vinorelbine in relapsed soft tissue sarcomas as shown by a Phase II trial by the Italian paediatric sarcoma group (Casanova et al, 2004) and an ongoing confirmatory phase II trial by the French group. Oral cyclophosphamide is given at a dose of 25 mg/m 2 daily for 28 days cycles.…”

Section: Concept and Objectivesmentioning

confidence: 99%

“…The efficacy of the combination of vinorelbine and cyclophosphamide (protracted oral low dose cylophosphamide) in relapsed paediatric sarcomas (41% response rate in 17 patients) (Casanova et al, 2004) has been confirmed in a large prospective phase II trial of 114 evaluable patients with relapsed or refractory malignant solid tumors. The overall response rate was 20% with complete and partial responses observed in 18/50 RMS (36%), 1/7 undifferentiated sarcoma, 2/15 Ewing, and 1/15 neuroblastoma (Oberlin et al, 2010).…”

Section: Concept and Objectivesmentioning

confidence: 99%